Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RABI-767 in Predicted Severe Acute Pancreatitis
NCT06080789Phase 2Recruiting
- Sponsor
- Panafina
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in acute pancreatitis (AP) comparing RABI-767 plus Standard-of-Care with Standard-of-Care Only (2 arms). Primary endpoints: Number of Participants with Adverse Events at Day 28, Number of Participants with Serious Adverse Events at Day 35 and 4 more. Started Jun 2024; status: recruiting.
02
Drugs
RABI-767
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT06080789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080789.